Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
multiple myeloma
Pharma
GSK's ADC Blenrep delivers survival win against J&J's Darzalex
The head-to-head overall survival win makes GSK’s £3 billion peak sales goal for the multiple myeloma antibody-drug conjugate look more attainable.
Angus Liu
Nov 14, 2024 9:24am
J&J angles Darzalex for first move into early-stage myeloma
Nov 8, 2024 9:53am
J&J, Legend's Carvykti shows 45% survival benefit in myeloma
Sep 30, 2024 9:50am
J&J counters Sanofi's Sarclisa nod with Darzalex data drop
Sep 27, 2024 3:59pm
BMS, 2seventy scrap Abecma trial in first-line multiple myeloma
Sep 25, 2024 10:52am
Sanofi moves on J&J's Darzalex in first-line myeloma with FDA nod
Sep 20, 2024 4:06pm
